• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Healthcare

Cramer: Papa's Got a Brand New Bag, and Leaves Perrigo Holding the Old One

Everything about the CEO's move to Valeant stinks.
By JIM CRAMER Apr 26, 2016 | 07:20 AM EDT
Stocks quotes in this article: PRGO, VRX, AGN, JNJ

Perrigo's (PRGO) heartbreaking. How could Joe Papa, the man who was so intertwined with Perrigo for so long, the man who came on Mad Money and argued there was so much more value to the company than the price Mylan put on it -- some 80 points higher than where it went out -- just leave for Valeant (VRX)? How could he leave with a huge shortfall and some weird impairment charge about an acquisition that Papa crowed about, Omega, as a way to get international exposure?

There wasn't a single thing that was kosher about what I heard from this company today even as the papers are filled this morning with how Papa is going to be an able ceo for Valeant establishing order. You mean order like the way he left Perrigo? How about disorder? How about disarray?

It made me so angry because I thought I knew Papa as a stand-up guy from his years of going on Mad Money. I thought that Papa had a good case for why Perrigo should have been valued much higher than where Mylan wanted to get it and that Perrigo was temporarily down on its luck.

I am indeed aghast that he fought against what would have been a great bid for shareholders. There's so many questions here. What is this potentially material charge? What happened with Omega? Why did the board withdraw Omega founder Marc Coucke's nomination for re-election to the board?

This is nothing less than a wholesale implosion of a company. Honestly, if you cut numbers from $9.52 to $8.20 to $8.60 but leave charges up in the air, why would anyone pay more than 10x earnings for this largely non-proprietary knock-off drugmaker? Mylan's at 9x earnings and that's a better company.

But you know what? As is the case with Valeant, everything that happened at Perrigo smacks of just a private company's whims even as both are very much public companies.

It stinks.

But I guess it doesn't matter. That's just the way the Perrigo crumbles.

As far as a read-through to other generic companies, that seems fanciful to me. The "old" Perrigo, before the mysterious "impairment" was largely a knock off company that thrived in cold and flu season and on vitamins that were made in America, as opposed to dumped Chinese competition.

To therefore hit Allergan (AGN), an Action Alerts PLUS portfolio stock, seems just ludicrous, especially given that it is selling its generic drug business to Teva.

Mylan was hit, but that might be a story of the company coming back with a stock-for-stock deal.

Ultimately, the real story about the earnings shortfall might be the relentless, inexorable share take by Johnson & Johnson (JNJ) against Perrigo. Remember, Perrigo was the real winner in the big McNeil labs recall. Their store brand competition to JNJ's once-pristine product line took a lot of share. But on the last quarterly conference call you saw a very robust JNJ taking back the shelves, with still a lot more to come.

I guess it was a pretty opportune time for Papa to jump ship, opportune for all but the shareholders of this once very good growth company that is now in tatters.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Action Alerts PLUS, which Cramer co-manages as a charitable trust, has a long position in AGN.

TAGS: Investing | U.S. Equity | Healthcare | Stocks

More from Healthcare

Boston Scientific Could Be Wicked Good in This Kind of Market

Brad Ginesin
May 24, 2022 2:13 PM EDT

Here's why this healthcare stock is a potential port in the storm for investors.

2 Biotech Stocks to Own as M&A Potentially Gathers Steam

Bret Jensen
May 11, 2022 11:35 AM EDT

I like these names as stand-alone entities but they should also attract interest from larger players.

China Faces 'Tsunami' of Covid Infection That Could Swamp the System

Alex Frew McMillan
May 11, 2022 9:00 AM EDT

A new study suggests 1.55 million people could die if China abandons zero-Covid, with the intensive-care system needing 15.6 times existing capacity.

I'm Giving Dynavax Another Shot -- a Booster Shot

Bret Jensen
May 8, 2022 7:31 AM EDT

Despite an earnings miss, DVAX show promise in several vaccine fronts and I'm doubling down on the name.

In This Environment, I'd Be More Risk Averse With Intuitive Surgical

Stephen Guilfoyle
Apr 25, 2022 10:50 AM EDT

The firm has been hurt and continues to be hurt by the effects of the pandemic.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 10:58 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    "The Tremendous Power of the Sell Button"
  • 02:46 PM EDT STEPHEN GUILFOYLE

    We're Shedding Some of This Holding on Strength

    Check out the Stocks Under $10 portfolio here!
  • 11:33 AM EDT PETER TCHIR

    Thoughts Ahead of the Fed Minutes

    Recent economic and earnings issues are convincing...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login